The ATS 2023 International Conference offers a robust scientific program highlighting the cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several sessions addressing new developments and considerations in interstitial lung disease and idiopathic pulmonary fibrosis, as listed below. A curated list of clinical and scientific sessions related to these topics also is available on the conference website. For more information on these and other sessions to be presented May 19–24 in Washington, DC, visit the online Program Itinerary.
- A1. Clinical Year in Review 1
- A88. Neuro-Immune Interactions in Lung Development and Disease
- B12. ATS Clinical Practice Guidelines: Clinical Practice on the Cutting Edge
- B82. The Genetics of Interstitial Lung Disease: Current State and Future Promise
- C2. Endpoints for Therapeutic Trials in ILD
- C83. Pro/Con: Hot Topics in Interstitial Lung Disease
- C86. Beyond the Transcriptome: How The Multi-“Omic” Universe Provides Novel Insights into IPF/ILD Pathogenesis
- D2. Cough in Pulmonary Fibrosis — Annoying Symptom or Driver/Marker of Disease Progression?
Extend Your Learning Beyond San Francisco with ATS 2025 Conference Highlights
With so many valuable educational opportunities offered during the ATS 2025 International Conference, attendees are often forced to decide which sessions to prioritize. That’s why the Society is offering three ATS 2025 Conference Highlights packages for those unable to attend ATS 2025 San Francisco or attendees interested in continuing their education after the conference. Check out the packages and pick the one that’s right for you. Learn at your own pace, whenever and wherever you are!